Microdissecting the role of microRNAs in the pathogenesis of prostate cancer

Cancer Genetics

Volumn 208, Issue 6, 2015, Pages 289-302

  Ayub, Shiekh Gazalla ^a   Kaul, Deepak ^a   Ayub, Taha ^b  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

Androgen dependent; Androgen independent; Castration resistant; Hormone sensitive; miRNAs; PCa

Indexed keywords

LET 7; MICRORNA; MICRORNA 101; MICRORNA 106B 25; MICRORNA 124; MICRORNA 125B; MICRORNA 133A; MICRORNA 133B; MICRORNA 143; MICRORNA 145; MICRORNA 148A; MICRORNA 15; MICRORNA 16; MICRORNA 200; MICRORNA 203; MICRORNA 205; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 23B; MICRORNA 27B; MICRORNA 31; MICRORNA 32; MICRORNA 34; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; GENE CLUSTER; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE SILENCING; GENETIC ASSOCIATION; HORMONAL REGULATION; HUMAN; MOLECULAR PATHOLOGY; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RNA ANALYSIS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; CELL PROLIFERATION; CELL SURVIVAL; GENETICS; MALE; ONCOGENE; TUMOR INVASION;

CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MICRORNAS; NEOPLASM INVASIVENESS; ONCOGENES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84937978756     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2015.02.010     Document Type: Review

References (150)

1. Ferlay J., Soerjomantaram I., Ervik M., et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 2013, [Internet], International Agency for Research on Cancer, Lyon, France, Available at:. http://globocan.iarc.fr.
2. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
3. Bushati N., Cohen S.M. microRNA functions. Annu Rev Cell Dev Biol 2007, 23:175-205.
4. Stefani G., Slack F.J. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 2008, 9:219-230.
5. Gangaraju V.K., Lin H. MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol 2009, 10:116-125.
6. Aqeilan R.I., Calin G.A., Croce C.M. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 2010, 17:215-220.
7. Jalava S.E., Urbanucci A., Latonen L., et al. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene 2012, 31:4460-4471.
8. Zaman M.S., Chen Y., Deng G., et al. The functional significance of microRNA-145 in prostate cancer. Br J Cancer 2010, 103:256-264.
9. Ribas J., Ni X., Haffner M., et al. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 2009, 69:7165-7169.
10. Volinia S., Calin G.A., Liu C.-G., et al. AmicroRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006, 103:2257-2261.
11. Porkka K.P., Pfeiffer M.J., Waltering K.K., et al. MicroRNA expression profiling in prostate cancer. Cancer Res 2007, 67:6130-6135.
12. Ambs S., Prueitt R.L., Yi M., et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008, 68:6162-6170.
13. Melamed J., Einhorn J.M., Ittmann M.M. Allelic loss on chromosome 13q in human prostate carcinoma. Clin Cancer Res 1997, 3:1867-1872.
14. Li C., Larsson C., Futreal A. Identification of two distinct deleted regions on chromosome 13 in prostate cancer. Oncogene 1998, 16:481-487.
15. Bonci D., Coppola V., Musumeci M., et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008, 14:1271-1277.
16. Almeida M., Han L., Bellido T., et al. Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. JBiol Chem 2005, 280:41342-41351.
17. Takeshita F., Patrawala L., Osaki M., et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 2010, 18:181-187.
18. Musumeci M., Coppola V., Addario A., et al. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene 2011, 30:4231-4242.
19. He L., He X., Lim L.P., et al. AmicroRNA component of the p53 tumour suppressor network. Nature 2007, 447:1130-1134.
20. Bommer G.T., Gerin I., Feng Y., et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007, 17:1298-1307.
21. Welch C., Chen Y., Stallings R.L. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007, 26:5017-5022.
22. Bagchi A., Mills A.A. The quest for the 1p36 tumor suppressor. Cancer Res 2008, 68:2551-2556.
23. Kong D., Heath E., Chen W., et al. Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. Am J Transl Res 2012, 4:14-23.
24. Kashat M., Azzouz L., Sarkar S.H., et al. Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness. Am J Transl Res 2012, 4:432-442.
25. Fujita Y., Kojima K., Hamada N., et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 2008, 377:114-119.
26. Östling P., Leivonen S.K., Aakula A., et al. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res 2011, 71:1956-1967.
27. Attard G., Richards J., de Bono J.S. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011, 17:1649-1657.
28. Rokhlin O.W., Scheinker V.S., Taghiyev A.F., et al. MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther 2008, 7:1288-1296.
29. Yamakuchi M., Ferlito M., Lowenstein C.J. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A 2008, 105:13421-13426.
30. Kojima K., Fujita Y., Nozawa Y., et al. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 2010, 70:1501-1512.
31. Lodygin D., Tarasov V., Epanchintsev A., et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008, 7:2591-2600.
32. Yamamura S., Saini S., Majid S., et al. MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS One 2012, 7:e29722.
33. Benassi B., Flavin R., Marchionni L., et al. MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer. Cancer Discov 2012, 2:236-247.
34. Majid S., Dar A.A., Saini S., et al. MicroRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications and AKT pathways. Clin Cancer Res 2013, 19:73-84.
35. Patrawala L., Calhoun-Davis T., Schneider-Broussard R., et al. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res 2007, 67:6796-6805.
36. Liu C., Kelnar K., Liu B., et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011, 17:211-215.
37. Clapé C., Fritz V., Henriquet C., et al. miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PloS One 2009, 4:e7542.
38. Friedman R.C., Farh K.K., Burge C.B., et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19:92-105.
39. Jiang S., Zhang L.F., Zhang H.W., et al. Anovel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J 2012, 31:1985-1998.
40. Suh S.O., Chen Y., Zaman M.S., et al. MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis 2011, 32:772-778.
41. Xu B., Niu X., Zhang X., et al. miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem 2011, 350:207-213.
42. Cai C., Portnoy D.C., Wang H., et al. Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2. Cancer Res 2009, 69:5202-5209.
43. White N.M.A., Youssef Y.M., Fendler A., et al. The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer. Biol Chem 2012, 393:379-389.
44. Fuse M., Nohata N., Kojima S., et al. Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol 2011, 38:1093-1101.
45. Chiyomaru T., Tatarano S., Kawakami K., et al. SWAP70, actin-binding protein, function as an oncogene targeting tumor-suppressive miR-145 in prostate cancer. Prostate 2011, 71:1559-1567.
46. Wu D., Huang P., Wang L., et al. MicroRNA-143 inhibits cell migration and invasion by targeting matrix metalloproteinase 13 in prostate cancer. Mol Med Rep 2013, 8:626-630.
47. Peng X., Guo W., Liu T., et al. Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PloS One 2011, 6:e20341.
48. Kojima S., Enokida H., Yoshino H., et al. The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. JHum Genet 2014, 59:78-87.
49. Huang S., Guo W., Tang Y., et al. miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells. Oncol Rep 2012, 28:1831-1837.
50. Vrba L., Jensen T.J., Garbe J.C., et al. Role for DNA Methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS One 2010, 5:e8697.
51. Thiery J.P., Acloque H., Huang R.Y.J., et al. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
52. Park S.M., Gaur A.B., Lengyel E., et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008, 22:894-907.
53. Kong D., Li Y., Wang Z., et al. miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 2009, 27:1712-1721.
54. Liu Y.N., Yin J.J., Abou-Kheir W., et al. MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene 2013, 32:296-306.
55. Slabáková E., Pernicová Z., Slavíčková E., et al. TGF-β1-induced EMT of non-transformed prostate hyperplasia cells is characterized by early induction of SNAI2/Slug. Prostate 2011, 71:1332-1343.
56. Williams L.V., Veliceasa D., Vinokour E., et al. miR-200b inhibits prostate cancer EMT, growth and metastasis. PLoS One 2013, 8:e83991.
57. Barron N., Keenan J., Gammell P., et al. Biochemical relapse following radical prostatectomy and miR-200a levels in prostate cancer. Prostate 2012, 72:1193-1199.
58. Kong D., Banerjee S., Ahmad A., et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 2010, 5:e12445.
59. Viticchiè G., Lena A.M., Latina A., et al. MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle 2011, 10:1121-1131.
60. Gandellini P., Folini M., Longoni N., et al. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res 2009, 69:2287-2295.
61. Wang N., Li Q., Feng N.-H., et al. miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth. Asian J Androl 2013, 15:735-741.
62. Bhatnagar N., Li X., Padi S.K.R., et al. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 2010, 1:e105.
63. Boll K., Reiche K., Kasack K., et al. MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene 2013, 32:277-285.
64. Dong Q., Meng P., Wang T., et al. MicroRNA let-7a inhibits proliferation of human prostate cancer cells invitro and invivo by targeting E2F2 and CCND2. PloS One 2010, 5:e10147.
65. Nadiminty N., Tummala R., Lou W., et al. MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS One 2012, 7:e32832.
66. Rybak A., Fuchs H., Smirnova L., et al. Afeedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. Nat Cell Biol 2008, 10:987-993.
67. Viswanathan S.R., Daley G.Q., Gregory R.I. Selective blockade of microRNA processing by Lin28. Science 2008, 320:97-100.
68. Viswanathan S.R., Powers J.T., Einhorn W., et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 2009, 41:843-848.
69. Dangi-Garimella S., Yun J., Eves E.M., et al. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J 2009, 28:347-358.
70. Lu J., Getz G., Miska E.A., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
71. Chang T.C., Zeitels L.R., Hwang H.W., et al. Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A 2009, 106:3384-3389.
72. Kumar M.S., Lu J., Mercer K.L., et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007, 39:673-677.
73. Leite K.R.M., Sousa-Canavez J.M., Reis S.T., et al. Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. Urol Oncol 2011, 29:265-269.
74. Nadiminty N., Tummala R., Lou W., et al. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. JBiol Chem 2012, 287:1527-1537.
75. Tummala R., Nadiminty N., Lou W., et al. Lin28 promotes growth of prostate cancer cells and activates the androgen receptor. Am J Pathol 2013, 183:288-295.
76. Kong D., Heath E., Chen W., et al. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PloS One 2012, 7:e33729.
77. Cao Q., Yu J., Dhanasekaran S.M., et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008, 27:7274-7284.
78. Varambally S., Cao Q., Mani R.S., et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008, 322:1695-1699.
79. Yu J., Cao Q., Mehra R., et al. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 2007, 12:419-431.
80. Hao Y., Gu X., Zhao Y., et al. Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway invivo. Cancer Prev Res (Phila) 2011, 4:1073-1083.
81. Palapattu G.S., Sutcliffe S., Bastian P.J., et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005, 26:1170-1181.
82. Ishteiwy R.A., Ward T.M., Dykxhoorn D.M., et al. The microRNA -23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells. PLoS One 2012, 7:e52106.
83. Fletcher C.E., Dart D.A., Sita-Lumsden A., et al. Androgen-regulated processing of the oncomir miR-27a, which targets Prohibitin in prostate cancer. Hum Mol Genet 2012, 21:3112-3127.
84. Tao J., Wu D., Xu B., et al. microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol Rep 2012, 27:1967-1975.
85. Lin P.C., Chiu Y.L., Banerjee S., et al. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res 2013, 73:1232-1244.
86. Yamasaki T., Yoshino H., Enokida H., et al. Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. Int J Oncol 2012, 40:1821-1830.
87. Lin S.L., Chang D., Ying S.Y. Hyaluronan stimulates transformation of androgen-independent prostate cancer. Carcinogenesis 2007, 28:310-320.
88. Lin S.L., Chiang A., Chang D., et al. Loss of mir-146a function in hormone-refractory prostate cancer. RNA 2008, 14:417-424.
89. Shi X.B., Xue L., Ma A.H., et al. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene 2013, 32:4130-4138.
90. Gong A.Y., Eischeid A.N., Xiao J., et al. miR-17-5p targets the p300/CBP-associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells. BMC Cancer 2012, 12:492.
91. Wang M., Ren D., Guo W., et al. Loss of miR-100 enhances migration, invasion, epithelial-mesenchymal transition and stemness properties in prostate cancer cells through targeting Argonaute 2. Int J Oncol 2014, 45:362-372.
92. Nishikawa R., Goto Y., Sakamoto S., et al. Tumor-suppressive microRNA-218 inhibits cancer cell migration and invasion via targeting of LASP1 in prostate cancer. Cancer Sci 2014, 105:802-811.
93. Maris J.M., Matthay K.K. Molecular biology of neuroblastoma. JClin Oncol 1999, 17:2264-2279.
94. Kasahara K., Taguchi T., Yamasaki I., et al. Detection of genetic alterations in advanced prostate cancer by comparative genomic hybridization. Cancer Genet Cytogenet 2002, 137:59-63.
95. Krichevsky A.M., Gabriely G. miR-21: a small multi-faceted RNA. JCell Mol Med 2009, 13:39-53.
96. Li T., Li D., Sha J., et al. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 2009, 383:280-285.
97. Zhang H.L., Yang L.F., Zhu Y., et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011, 71:326-331.
98. Li T., Li R.S., Li Y.H., et al. miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer. JUrol 2012, 187:1466-1472.
99. Fujita S., Ito T., Mizutani T., et al. miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. JMol Biol 2008, 378:492-504.
100. Ouyang X., Jessen W.J., Al-Ahmadie H., et al. Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res 2008, 68:2132-2144.
101. Mora L.B., Buettner R., Seigne J., et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002, 62:6659-6666.
102. Barton B.E., Karras J.G., Murphy T.F., et al. Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 2004, 3:11-20.
103. Arbuzova A., Schmitz A.A.P., Vergères G. Cross-talk unfolded: MARCKS proteins. Biochem J 2002, 362:1-12.
104. Coppola V., Musumeci M., Patrizii M., et al. BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition. Oncogene 2013, 32:1843-1853.
105. Goldstein A.S., Huang J., Guo C., et al. Identification of a cell of origin for human prostate cancer. Science 2010, 329:568-571.
106. Lawson D.A., Zong Y., Memarzadeh S., et al. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A 2010, 107:2610-2615.
107. Liu L.Z., Li C., Chen Q., et al. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression. PLoS One 2011, 6:e19139.
108. Reis S.T., Pontes-Junior J., Antunes A.A., et al. miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer. BMC Urol 2012, 12:14.
109. Shi G., Ye D., Yao X., et al. Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin 2010, 31:867-873.
110. Sun Z., Li S., Kaufmann A.M., et al. miR-21 increases the programmed cell death 4 gene-regulated cell proliferation in head and neck squamous carcinoma cell lines. Oncol Rep 2014, 32:2283-2289.
111. Li L., Zhou L., Li Y., et al. MicroRNA-21 stimulates gastric cancer growth and invasion by inhibiting the tumor suppressor effects of programmed cell death protein 4 and phosphatase and tensin homolog. JBUON 2014, 19:228-236.
112. Folini M., Gandellini P., Longoni N., et al. miR-21: an oncomir on strike in prostate cancer. Mol Cancer 2010, 9:12.
113. Mishra S., Deng J.J., Gowda P.S., et al. Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. Oncogene 2014, 33:4097-4106.
114. Ciafrè S.A., Galardi S., Mangiola A., et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 2005, 334:1351-1358.
115. Gottardo F., Liu C.G., Ferracin M., et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007, 25:387-392.
116. Galardi S., Mercatelli N., Giorda E., et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. JBiol Chem 2007, 282:23716-23724.
117. Sun T., Wang Q., Balk S., et al. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res 2009, 69:3356-3363.
118. Fuse M., Kojima S., Enokida H., et al. Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer. JHum Genet 2012, 57:691-699.
119. Zheng C., Yinghao S., Li J. MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2. Med Oncol 2012, 29:815-822.
120. Mercatelli N., Coppola V., Bonci D., et al. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One 2008, 3:e4029.
121. Hu L., Ibrahim S., Liu C., et al. Thrombin induces tumor cell cycle activation and spontaneous growth by down-regulation of p27Kip1, in association with the up-regulation of Skp2 and MiR-222. Cancer Res 2009, 69:3374-3381.
122. Sun T., Wang X., He H.H., et al. MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene 2014, 33:2790-2803.
123. Chen Y., Zaman M.S., Deng G., et al. MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer. Cancer Prev Res (Phila) 2011, 4:76-86.
124. Lin D., Cui F., Bu Q., et al. The expression and clinical significance of GTP-binding RAS-like 3 (ARHI) and microRNA 221 and 222 in prostate cancer. JInt Med Res 2011, 39:1870-1875.
125. Shi X.B., Xue L., Yang J., et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A 2007, 104:19983-19988.
126. Lee Y.S., Kim H.K., Chung S., et al. Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. JBiol Chem 2005, 280:16635-16641.
127. Isaacs W.B., Carter B.S., Ewing C.M. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 1991, 51:4716-4720.
128. Ozen M., Creighton C.J., Ozdemir M., et al. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008, 27:1788-1793.
129. Scott G.K., Goga A., Bhaumik D., et al. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. JBiol Chem 2007, 282:1479-1486.
130. Ren B., Yu G., Tseng G.C., et al. MCM7 amplification and overexpression are associated with prostate cancer progression. Oncogene 2006, 25:1090-1098.
131. Hudson R.S., Yi M., Esposito D., et al. MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer. Oncogene 2013, 32:4139-4147.
132. Poliseno L., Salmena L., Riccardi L., et al. Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal 2010, 3:ra29.
133. Li B., Shi X.B., Nori D., et al. Down-regulation of microRNA 106b is involved in p21-mediated cell cycle arrest in response to radiation in prostate cancer cells. Prostate 2011, 71:567-574.
134. Muthalagu N., Junttila M.R., Wiese K.E., et al. BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues. Cell Rep 2014, 8:1347-1353.
135. Li X., Xin S., He Z., et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor PDCD4 and promotes cell transformation, proliferation, and metastasis in renal cell carcinoma. Cell Physiol Biochem 2014, 33:1631-1642.
136. Walter B.A., Valera V.A., Pinto P.A., et al. Comprehensive microRNA profiling of prostate cancer. JCancer 2013, 4:350-357.
137. Murata T., Takayama K., Katayama S., et al. miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. Prostate Cancer Prostatic Dis 2010, 13:356-361.
138. Fujita Y., Kojima K., Ohhashi R., et al. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. JBiol Chem 2010, 285:19076-19084.
139. Ma S., Chan Y.P., Kwan P.S., et al. MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2. Cancer Res 2011, 71:583-592.
140. Cheng P., Li R., Lin B., et al. Effect of miR-296 on the apoptosis of androgen-independent prostate cancer cells. JReprod Contracept 2009, 20:1-9.
141. Lodygin D., Epanchintsev A., Menssen A., et al. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005, 65:4218-4227.
142. Wu Z., He B., He J., et al. Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer. Prostate 2013, 73:596-604.
143. Trang P., Wiggins J.F., Daige C.L., et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011, 19:1116-1122.
144. van Rooij E., Sutherland L.B., Qi X., et al. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007, 316:575-579.
145. Lanford R.E., Hildebrandt-Eriksen E.S., Petri A., et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327:198-201.
146. Fleming N.H., Zhong J., da Silva I.P., et al. Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients. Cancer 2015, 121:51-59.
147. Zhi F., Shao N., Wang R., et al. Identification of 9 serum micro-RNAs as potential noninvasive biomarkers of human astrocytoma. Neuro Oncol 2015, 17:383-391.
148. Bryant R.J., Pawlowski T., Catto J.W.F., et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012, 106:768-774.
149. Chen Z.H., Zhang G.L., Li H.R., et al. Apanel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate 2012, 72:1443-1452.
150. Fan X., Chen X., Deng W., et al. Up-regulated microRNA-143 in cancer stem cells differentiation promotes prostate cancer cells metastasis by modulating FNDC3B expression. BMC Cancer 2013, 13:61.